[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit ::
:: Volume 7, Issue 1 (Winter - 2019) ::
Shefaye Khatam 2019, 7(1): 63-76 Back to browse issues page
A Review on the Structural and Metabolic Biomarkers in Migraine
Fereshteh Dalouchi, Fatemeh Moradi, Mostafa Modarres Mousavi Sayed, Fariba Karimzadeh *
Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran , kaimzade.f@iums.ac.ir
Abstract:   (495 Views)
Introduction: Migraine is a neurovascular illness with repeated attacks of modest to intense headache, lasting 4–72 hours and linked to nausea, vomiting, and sensitivity to light and noise. Migraine is often associated with asthma, anxiety, depression, and chronic pain. Recent development in basic and clinical investigations has augmented our grasp of the pathophysiology of these headaches. New drugs and treatment for the improvement of these headaches are emergent. Therefore, biomarkers provide a dynamic and a potent indicator to understanding the spectrum of neurological disease with applications in observational and analytic epidemiology, randomized clinical trials, screening and analysis and forecast. Biomarkers can also reflect the entire spectrum of disease from the earliest manifestations to the terminal stages. Conclusion: This review discusses the definition and uses of migraine biomarkers, particularly their role in diagnosis, risk stratification and management of disease.
Keywords: Migraine Disorders, Biomarkers, Headache, Brain
Full-Text [PDF 996 kb]   (154 Downloads)    
Type of Study: Review --- Open Access, CC-BY-NC | Subject: Molecular Neurobiology
References
1. Beres SJ, Liu GT. New advancements in migraine assessment and treatment. Advances in Ophthalmology and Optometry. 2016; 1(1): 249-60. [DOI:10.1016/j.yaoo.2016.03.005]
2. Goadsby P, Schoenen J, Ferrari M, Silberstein S, Dodick D. Towards a definition of intractable headache for use inclinical practice and trials. Cephalalgia. 2006; 26(9): 1168-70. [DOI:10.1111/j.1468-2982.2006.01173.x]
3. Edvinsson L, Villalón CM, MaassenVanDenBrink A. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther. 2012; 136(3): 319-33. [DOI:10.1016/j.pharmthera.2012.08.011]
4. Pascual J. CGRP antibodies: theholy grail for migraine prevention? Lancet Neurol. 2015; 14(11): 1066-7. [DOI:10.1016/S1474-4422(15)00244-6]
5. EvANs RW. The clinical features of migraine with and without aura. Pract Neurol. 2014; 13: 26-32.
6. Olesen J, Ashina M. Emerging migraine treatments and drug targets. Trends Pharmacol Sci. 2011; 32(6): 352-9. [DOI:10.1016/j.tips.2011.02.016]
7. Zagami AS. Pathophysiology of migraine and tension-type headache. Curr Opin Neurol. 1994; 7(3): 272-7. [DOI:10.1097/00019052-199406000-00016]
8. Wessman M, Terwindt GM, Kaunisto MA, Palotie A, Ophoff RA. Migraine: a complex genetic disorder. Lancet Neurol. 2007; 6(6): 521-32. [DOI:10.1016/S1474-4422(07)70126-6]
9. Ligthart L, Boomsma DI, Martin NG, Stubbe JH, Nyholt DR. Migraine with aura and migraine without aura are not distinct entities: further evidence from a large dutch population study. Twin Res Hum Genet. 2006; 9(1): 54-63. [DOI:10.1375/twin.9.1.54]
10. Finkel AG, Yerry JA, Mann JD. Dietary considerations in migraine management: does a consistent diet improve migraine? Curr Pain Headache Rep. 2013; 17(11): 373. doi: 10.1007/s11916-013-0373-4. [DOI:10.1007/s11916-013-0373-4]
11. Ramadan NM, Buchanan TM. New andfuture migraine therapy. Pharmacol Ther. 2006; 112(1): 199-212. [DOI:10.1016/j.pharmthera.2005.04.010]
12. Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017; 16(1): 76-87. [DOI:10.1016/S1474-4422(16)30293-9]
13. Tietjen GE, Khubchandani J, Herial NA, Shah K. Adverse childhood experiences are associated with migraine and vascular biomarkers. Headache. 2012; 52(6): 920-9. [DOI:10.1111/j.1526-4610.2012.02165.x]
14. Van der Schueren BJ, Verbrugge FH, Verbesselt R, Hecken AV, Depré M, de Hoon JN. No arguments for increased endothelial nitric oxide synthase activity in migraine based on peripheral biomarkers. Cephalalgia. 2010; 30(11): 1354-65. [DOI:10.1177/0333102410365105]
15. Kokavec A. Migraine: A disorder of metabolism? Med Hypotheses. 2016; 97: 117-30. [DOI:10.1016/j.mehy.2016.10.029]
16. Salmito MC, Duarte JA, Morganti LOG, Brandão PVC, Nakao BH, Villa TR, et al. Prophylactic treatment of vestibular migraine. Braz J Otorhinolaryngol. 2017; 83(4): 404-10. [DOI:10.1016/j.bjorl.2016.04.022]
17. Benoit DP. An introduction to migraine pathophysiology. Tech Reg Anesth Pain Manag. 2009; 13(1): 5-8. [DOI:10.1053/j.trap.2009.04.002]
18. Durham P, Papapetropoulos S. Biomarkers associated with migraine and their potential role in migraine management. Headache. 2013; 53(8): 1262-77. [DOI:10.1111/head.12174]
19. Just S, Arndt K, Weiser T, Doods H. Pathophysiology of migraine: a role for neuropeptides. Drug discovery today: Disease Mechanisms. 2006; 3(3): 327-33. [DOI:10.1016/j.ddmec.2006.07.002]
20. Zargaran A, Borhani-Haghighi A, Faridi P, Daneshamouz S, Mohagheghzadeh A. A review on the managementof migraine in the avicenna's canon of medicine. Neurol Sci. 2016; 37(3): 471-8. [DOI:10.1007/s10072-016-2498-9]
21. Hargreaves R, Shepheard S. Pathophysiology of migraine-new insights. Can J Neurol Sci. 1999; 26(3): 12-9. [DOI:10.1017/S0317167100000147]
22. Kacperski J, Hershey AD. Newly approved agents for the treatment and prevention of pediatric migraine. CNS Drugs. 2016; 30(9): 837-44. [DOI:10.1007/s40263-016-0375-y]
23. Stone MT, Weed V, Kulich RJ. Opioid treatment of migraine: Risk factors and behavioral issues. Curr Pain Headache Rep. 2016; 20(9): 51. doi: 10.1007/s11916-016-0581-9. [DOI:10.1007/s11916-016-0581-9]
24. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016; 12(8): 455-64. [DOI:10.1038/nrneurol.2016.93]
25. Hargreaves RJ, Lines CR, Rapoport AM, Ho TW, Sheftell FD. Ten years of rizatriptan: from development to clinical science and future directions. Headache. 2009; 49: S3-S20. [DOI:10.1111/j.1526-4610.2008.01335.x]
26. Aronson JK. Biomarkers and surrogate endpoints. Br J Clin Pharmacol. 2005; 59(5): 491-4. [DOI:10.1111/j.1365-2125.2005.02435.x]
27. Vaughan L. Biomarkers in acute medicine. Medicine. 2013; 41(3): 136-41. [DOI:10.1016/j.mpmed.2013.01.001]
28. Tanaka T, Tanaka M, Tanaka T, Ishigamori R. Biomarkers for colorectal cancer. Int J Mol Sci. 2010; 11(9): 3209-25. [DOI:10.3390/ijms11093209]
29. McCormick T, Martin K, Hehenberger M. The evolving role of biomarkers: Focusing on patients from research to clinical practice. IBM Global Business Services. 2007.
30. Mayeux R. Biomarkers: potential uses and limitations. NeuroRx. 2004; 1(2): 182-8. [DOI:10.1602/neurorx.1.2.182]
31. Gârban Z, Avacovici A, Gârban G, Ghibu G, Velciov AB, Pop CI. Biomarkers: theoretical aspects and applicative peculiarities note i. general characteristics of biomarkers. Agroalimentary Process Technol. 2005; 11: 139-46.
32. Polivka J, Krakorova K, Peterka M, Topolcan O. Current status of biomarker research in neurology. EPMA Journal. 2016; 7(1): 14. doi: 10.1186/s13167-016-0063-5. [DOI:10.1186/s13167-016-0063-5]
33. Dahlem MA, Kurths J, Ferrari MD, Aihara K, Scheffer M, May A. Understanding migraine using dynamic network biomarkers. Cephalalgia. 2015; 35(7): 627-30. [DOI:10.1177/0333102414550108]
34. Dahlem M, Rode S, May A, Fujiwara N, Hirata Y, Aihara K, et al. Towards dynamical network biomarkers in neuromodulation of episodic migraine. Translational Neuroscience. 2013; 4(3): 282-94. [DOI:10.2478/s13380-013-0127-0]
35. Kondratieva N, Azimova J, Skorobogatykh K, Sergeev A, Naumova E, Kokaeva Z, et al. Biomarkers of migraine: Part 1–Genetic markers. J Neurol Sci. 2016; 369: 63-76. [DOI:10.1016/j.jns.2016.08.008]
36. van Dongen RM, Zielman R, Noga M, Dekkers OM, Hankemeier T, van den Maagdenberg AM, et al. Migraine biomarkers in cerebrospinal fluid: a systematic review and meta-analysis. Cephalalgia. 2017; 37(1): 49-63. [DOI:10.1177/0333102415625614]
37. Schwedt TJ, Chiang C-C, Chong CD, Dodick DW. Functional MRI of migraine. The Lancet Neurology. 2015; 14(1): 81-91. [DOI:10.1016/S1474-4422(14)70193-0]
38. Wang M, Su J, Zhang J, Zhao Y, Yao Q, Zhang Q, et al. Visual cortex and cerebellum hyperactivation during negative emotion picture stimuli in migraine patients. Sci Rep. 2017; 7: 41919. doi: 10.1038/srep41919. [DOI:10.1038/srep41919]
39. Tietjen GE, Khubchandani J. Vascular biomarkers in migraine. Cephalalgia. 2015; 35(2): 95-117. [DOI:10.1177/0333102414544976]
40. Ishizaki K, Takeshima T, Fukuhara Y, Araki H, Nakaso K, Kusumi M, et al. Increased plasma transforming growth factor‐β1 in migraine. Headache. 2005; 45(9): 1224-8. [DOI:10.1111/j.1526-4610.2005.00246.x]
41. Kurth T, Ridker P, Buring J. Migraine and biomarkers of cardiovascular disease in women. Cephalalgia. 2008; 28(1): 49-56. [DOI:10.1111/j.1468-2982.2007.01467.x]
42. Tietjen GE, Herial NA, White L, Utley C, Kosmyna JM, Khuder SA. Migraine and biomarkers of endothelial activation in young women. Stroke. 2009; 40(9): 2977-82. [DOI:10.1161/STROKEAHA.109.547901]
43. Yilmaz N, Aydin O, Yegin A, Tiltak A, Eren E. Increased levels of total oxidant status and decreased activity of arylesterase in migraineurs. Clin Biochem. 2011; 44(10-11): 832-7. [DOI:10.1016/j.clinbiochem.2011.04.015]
44. Harrington MG. Cerebrospinal fluid biomarkers in primary headache disorders. Headache. 2006; 46(7): 1075-87. [DOI:10.1111/j.1526-4610.2006.00501.x]
45. Aguila M-ER,Rebbeck T, Leaver AM, Lagopoulos J, Brennan PC, Hübscher M, et al. The association between clinical characteristics of migraine and brain GABA levels: an exploratory study. J Pain. 2016; 17(10): 1058-67. [DOI:10.1016/j.jpain.2016.06.008]
46. Tajti J, Szok D, Majláth Z, TukaB, Csáti A, Vécsei L. Migraine and neuropeptides. Neuropeptides. 2015; 52: 19-30. [DOI:10.1016/j.npep.2015.03.006]
47. Matesanz F, Fedetz M, Barrionuevo C, Karaky M, Catalá-Rabasa A, Potenciano V, et al. A splice variant in the ACSL5 gene relates migraine with fatty acid activation in mitochondria. EEur J Hum Genet. 2016; 24(11): 1572-7. [DOI:10.1038/ejhg.2016.54]
48. Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013; 81(14): 1191-6. [DOI:10.1212/WNL.0b013e3182a6cb72]
49. Isobe C, Terayama Y. A remarkable increase in total homocysteine concentrations in the CSF of migraine patients with aura. Headache. 2010; 50(10): 1561-9. [DOI:10.1111/j.1526-4610.2010.01713.x]
50. De Vries B, Haan J, Frants RR, Vanden Maagdenberg AM, Ferrari MD. Genetic biomarkers for migraine. Headache. 2006; 46(7): 1059-68. [DOI:10.1111/j.1526-4610.2006.00499.x]
51. Fernandez F, Colson N, Griffiths LR. Pharmacogenetics of migraine: genetic variants and their potential role in migraine therapy.Pharmacogenomics. 2007; 8(6): 609-22. [DOI:10.2217/14622416.8.6.609]
52. De Vries B, Frants RR, Ferrari MD, van den Maagdenberg AM. Molecular genetics of migraine. Hum Genet. 2009; 126(1): 115-32. [DOI:10.1007/s00439-009-0684-z]
53. Hershey AD. Genetics of migraine headache in children. Current Pain and Headache Reports. 2007; 11(5): 390-5. [DOI:10.1007/s11916-007-0222-4]
54. Nagata E, Hattori H, Kato M, Ogasawara S, Suzuki S, Shibata M, et al. Identification of biomarkers associated with migraine with aura. Neurosci Res. 2009; 64(1): 104-10. [DOI:10.1016/j.neures.2009.02.001]
55. Imamura K, Takeshima T, Fusayasu E, Nakashima K. Increased plasma matrix metalloproteinase‐9 levels in migraineurs. Headache. 2008; 48(1): 135-9.
56. Olesen J, Diener H-C, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene–related peptide receptor antagonist BIBN 4096BS for the acute treatment of migraine. N Engl J Med. 2004; 350(11): 1104-10. [DOI:10.1056/NEJMoa030505]
57. Aluise CD, Sowell RA, Butterfield DA. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoringof therapeutic efficacy of Alzheimer's disease. Biochim Biophys Acta. 2008; 1782(10): 549-58. [DOI:10.1016/j.bbadis.2008.07.008]
58. Ceylan M, Bayraktutan OF, Becel S, Atis Ö, Yalcin A, Kotan D. Serum levels of pentraxin-3 and other inflammatory biomarkers in migraine: association with migraine characteristics. Cephalalgia. 2016; 36(6): 518-25. [DOI:10.1177/0333102415598757]
59. Gonzalez-Cuyar LF, Sonnen JA, Montine KS, Keene CD, Montine TJ. Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerativedisorders and mild cognitive impairment. Curr Neurol Neurosci Rep. 2011; 11(5): 455-63. [DOI:10.1007/s11910-011-0212-0]
60. Szalárdy L, Zádori D, Klivényi P, Vécsei L. The role of cerebrospinal fluid biomarkers in the evolution of diagnostic criteria in Alzheimer's disease: Shortcomings in prodromal diagnosis. J Alzheimers Dis. 2016; 53(2): 373-92. [DOI:10.3233/JAD-160037]



XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Dalouchi F, Moradi F, Modarres Mousavi M, Karimzadeh F. A Review on the Structural and Metabolic Biomarkers in Migraine. Shefaye Khatam. 2019; 7 (1) :63-76
URL: http://shefayekhatam.ir/article-1-1868-en.html


Volume 7, Issue 1 (Winter - 2019) Back to browse issues page
مجله علوم اعصاب شفای خاتم The Neuroscience Journal of Shefaye Khatam
Persian site map - English site map - Created in 0.06 seconds with 31 queries by YEKTAWEB 3877